Exavir Settles, Licenses Ultra-Long HIV Compounds To ViiV
22 May 2024 //
BUSINESSWIRE
Exavir Receives $3M Award from NIH / NIAID to Advance Inhibitor XVIR-110
22 Aug 2023 //
BUSINESSWIRE
GSK’s ViiV Sues Exavir Over Licensing Pact on HIV-Drug Compounds
01 Nov 2022 //
BLOOMBERGLAW
Exavir to publish PC data for ultra-long-acting dolutegravir prodrug XVIR-120
09 Jun 2022 //
GLOBENEWSWIRE
Exavir Therapeutics Completes $4M Seed Financing from Key Investors
23 May 2022 //
GLOBENEWSWIRE